The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer

The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Kenji Shibuta Hiroaki Ueo Hidemi Furusawa Kansei Komaki Yoshiaki Rai Yoshiatsu Sagara Yoshihiko Kamada Nobumitsu Tamaki
  • چاپ و سال / کشور: 2009

Description

Background Estrogen receptor (ER), progesterone receptor (PgR), and HER2 expression status in breast cancer function as prognostic and predictive factors that enable individualized treatment. Intrinsic subtype classification has also been performed based on these and other biological and prognostic characteristics. However, clinical analysis of such subtypes in a large number of Japanese breast cancer patients has not yet been reported. Methods Between January 2003 and December 2007, 4,266 patients with primary breast cancer were registered. Four subtypes based on immunohistochemically evaluated ER/PgR/HER2 status, clinicopathological features, and prognosis were analyzed retrospectively. Results The following subtype distribution was observed: luminal A type (ER? and/or PgR?, HER2-), 3,046 cases (71%); luminal B type (ER? and/or PgR?, HER2?), 321 cases (8%); HER2 type (ER-, PgR-, HER2?), 398 cases (9%); and triple negative (TN) type (ER-, PgR-, HER2-), 501 cases (12%). The HER2? subtypes (luminal B and HER2 types) had a significantly higher incidence of lymph node metastasis and lymphatic permeation, while the hormone receptor negative subtypes (HER2 and TN types) showed a significantly higher nuclear grade. Overall, patients with HER2-type and TN-type disease had a significantly poorer prognosis than other subtypes. Conclusion Intrinsic breast cancer subtypes are associated with clinicopathological features and prognosis in Japanese women. Long-term clinical observation of the relationship between each subtype and therapies used should provide useful information for selecting appropriately tailored treatments.
Breast Cancer DOI 10.1007/s12282-010-0209-6 Received: 15 December 2009 / Accepted: 7 May 2010  The Japanese Breast Cancer Society 2010
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری